Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Petrelli F, Rulli E, Labianca R, Lonardi S, Rosati G, Dotti K, Ronzoni M, Pella N, Pusceddu V, Banzi M, Zampino MG, Yasmina M, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Sobrero A; TOSCA Investigators. Petrelli F, et al. Among authors: pusceddu v. Ann Oncol. 2021 Jan;32(1):66-76. doi: 10.1016/j.annonc.2020.10.477. Epub 2020 Oct 21. Ann Oncol. 2021. PMID: 33098997 Free article. Clinical Trial.
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M. Demurtas L, et al. Among authors: pusceddu v. Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20. Br J Cancer. 2017. PMID: 28632725 Free PMC article.
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.
Schirripa M, Pasqualetti G, Giampieri R, Scartozzi M, Lonardi S, Rumanò L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, Rizzato MD, Prete AA, Puzzoni M, Pusceddu V, Ziranu P, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. Schirripa M, et al. Among authors: pusceddu v. Clin Colorectal Cancer. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 30149875
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. Petrelli F, et al. Among authors: pusceddu v. JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486. JAMA Oncol. 2020. PMID: 32053133 Free PMC article. Clinical Trial.
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy.
Giampieri R, Ziranu P, Daniele B, Zizzi A, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Casagrande M, Pella N, Demurtas L, Zampino MG, Sozzi P, Pusceddu V, Germano D, Lai E, Zagonel V, Codecà C, Libertini M, Puzzoni M, Labianca R, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: pusceddu v. Cancers (Basel). 2020 May 22;12(5):1330. doi: 10.3390/cancers12051330. Cancers (Basel). 2020. PMID: 32456056 Free PMC article.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Among authors: pusceddu v. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
Ziranu P, Lai E, Schirripa M, Puzzoni M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. Ziranu P, et al. Among authors: pusceddu v. Target Oncol. 2021 Jul;16(4):517-527. doi: 10.1007/s11523-021-00816-3. Epub 2021 May 10. Target Oncol. 2021. PMID: 33970400 Free PMC article.
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.
Lai E, Puzzoni M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente, Italian Group for the Study of Gastrointestinal Tumors). Lai E, et al. Among authors: pusceddu v. Clin Colorectal Cancer. 2021 Dec;20(4):e253-e262. doi: 10.1016/j.clcc.2021.07.008. Epub 2021 Jul 31. Clin Colorectal Cancer. 2021. PMID: 34429245
44 results